GLP2-Tirz
STRONG EVIDENCEAlso known as: Tirzepatide analogue
Analogue of an approved drug substance — research supply is NOT an approved medicine
Educational Overview
A dual GIP/GLP-1 receptor agonist analogue. The reference molecule has been extensively studied in large controlled trials and is the active ingredient of FDA-approved prescription products.
Research Mechanism
Dual agonism at GIP and GLP-1 receptors affects insulin secretion, gastric emptying, and satiety signalling — among the best-characterised mechanisms in this catalog.
Areas of Study
- Glycaemic control (clinical)
- Body-weight regulation (clinical)
Safety Considerations
IMPORTANT: research-supplied material is not an approved medicine, is not manufactured to pharmaceutical standards, and is not interchangeable with prescription products. Not for human use. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.